Trials / Completed
CompletedNCT02394886
Safety of ALLO-ASC-DFU in the Patients With Diabetic Foot Ulcers
A Phase I Clinical Study to Evaluate the Safety of ALLO-ASC-DFU in the Patients With Diabetic Foot Ulcers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Anterogen Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase I open-label study to evaluate the safety of ALLO-ASC-DFU in diabetic foot ulcers patients. ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide an new option in treating a diabetic foot ulcer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ALLO-ASC-DFU |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2015-05-01
- Completion
- 2015-07-01
- First posted
- 2015-03-20
- Last updated
- 2015-10-16
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02394886. Inclusion in this directory is not an endorsement.